Cantor Fitzgerald raised the firm’s price target on Eupraxia Pharmaceuticals (EPRX) to $19 from $11 and keeps an Overweight rating on the shares. Eupraxia was named a top pick by Cantor, which tells investors in a research note that the firm would own the name ahead of the Phase 2b data expected in Q3.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating
- Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI
- Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial
- Promising Prospects for Eupraxia Pharmaceuticals’ EP-104GI in Eosinophilic Esophagitis Treatment